Foreign media commentary suggests that artificial general intelligence ( AGI ) is expected to enhance the efficiency of drug development and may even help in conquering more diseases, but there is still a significant gap between this goal and its practical application. The article points out that AI does demonstrate speed advantages in molecular screening, data analysis, and clinical design; however, being "faster" does not equate to "quickly curing diseases."
AI has accelerated in drug discovery
The article mentions that traditional drug discovery typically involves repeated trial and error centered around genes, proteins, and molecular structures, resulting in long development cycles and high costs. Many breakthroughs are accidental. The value of AI lies in its ability to process data volumes far beyond human capabilities and to identify more viable candidate solutions from the complex relationships between proteins and molecules.
The author cites academic research stating that AI is shifting some processes that previously relied on “luck” to more structured screening methods. Such systems can identify potential drug combinations more quickly and also help to improve the efficiency of discovering drugs suitable for commercialization.
Costs and timelines are expected to decrease.
Another cited study suggests that the use of AI in辅助 drug development has led to improvements in patient recruitment, data processing, and clinical trial design, thereby reducing some of the development costs and time. This is particularly important for the pharmaceutical industry, as bringing new drugs to market often requires years of investment and substantial funds.
If AI can continue to reduce resource consumption in the R&D process, it could theoretically also alleviate some of the pressure on drug prices. The article argues that this is also one of the important reasons why the market maintains a high level of interest in the medical prospects of AGI.
Clinical trials and data remain bottlenecks.
However, the article also emphasizes that even if AGI's capabilities continue to improve, they cannot bypass the constraints of real-world clinical trials. Drug validation ultimately involves real patients, ethical review, and long-term observation, which are difficult to simply compress.
The author also pointed out that the effectiveness of the AI system depends on the quality and completeness of the input data, which is still scattered across different institutions and systems. AI can help to integrate this information, but the prerequisite is still to have access to sufficient data and clear guidelines for its use.
Policy coordination still needs to be advanced.
The article concludes that for medical AGI to be applied on a larger scale, in addition to technological progress, more consistent policy arrangements and security constraints are also required. The reason is that once such systems are involved in disease treatment and clinical decision-making, they affect not only the efficiency of research and development but also patient safety and the division of responsibilities.
Overall, this comment does not deny the role of AGI in driving medical research and development, but the core conclusion is that AI is more likely to become an accelerator for drug discovery and trial design first, rather than directly "curing all diseases" in the short term.
